Monte Rosa Therapeutics Inc (GLUE)vsBeiGene, Ltd. (ONC)
GLUE
Monte Rosa Therapeutics Inc
$15.50
-2.15%
HEALTHCARE · Cap: $2.00B
ONC
BeiGene, Ltd.
$347.48
-2.40%
HEALTHCARE · Cap: $40.64B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 14169% more annual revenue ($6.13B vs $42.95M). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
GLUE
Avoid23
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLUE.
Margin of Safety
+80.3%
Fair Value
$1785.72
Current Price
$347.48
$1438.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.9% — below average capital efficiency
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GLUE
The strongest argument for GLUE centers on Debt/Equity, Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : GLUE
The primary concerns for GLUE are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.2x leaves little room for execution misses.
Key Dynamics to Monitor
GLUE profiles as a value stock while ONC is a growth play — different risk/reward profiles.
GLUE carries more volatility with a beta of 1.56 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 23/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Monte Rosa Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?